×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Gland Pharma Limited | 10935.76 | 2692.58 | 10388.35 | 16.34 | 30,943 | 40.2 |
| Krishna Institute of Medical S | 3856.0 | 588.0 | 3734.0 | 1.47 | 29450 | 79.8 |
| J.B.CHEMICALS & PHARMACEUTICAL | 10538.0 | 1978.7 | 10399.0 | 12.48 | 27013 | 39.4 |
Gland Pharma Limited, with Security Code 543245, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 785.4 | 884.1 | 1,010.7 | 1,097.9 | 1,174.8 | 1,012.0 | 1,063.0 | 1,010.8 | 1,030.4 | 1,038.8 |
| Expenses | 616.3 | 624.7 | 663.6 | 728.4 | 742.0 | 718.5 | 699.2 | 619.6 | 636.2 | 680.0 |
| Operating Profit | 169.2 | 259.4 | 347.1 | 369.5 | 432.8 | 293.6 | 363.8 | 391.1 | 394.2 | 358.8 |
| OPM % | 21.54% | 29.34% | 34.34% | 33.66% | 36.84% | 29.01% | 34.22% | 38.7% | 38.26% | 34.54% |
| Other Income | -17.5 | 35.2 | 41.1 | 43.4 | 47.0 | 48.5 | 57.8 | 65.1 | 43.7 | 54.7 |
| Interest | 2.2 | 1.6 | 0.9 | 0.8 | 4.5 | 0.9 | 0.2 | 18.3 | 3.4 | 7.4 |
| Depreciation | 37.5 | 39.0 | 40.2 | 40.3 | 42.6 | 40.8 | 41.6 | 43.8 | 43.1 | 43.8 |
| Profit before tax | 168.4 | 254.0 | 347.1 | 371.8 | 432.7 | 300.3 | 379.8 | 394.1 | 391.4 | 362.4 |
| Tax % | -29.2% | -26.1% | -25.8% | -25.5% | -25.7% | -25.8% | -25.8% | -25.1% | -25.9% | 25.7% |
| Net Profit | 79.2 | 187.6 | 257.5 | 276.8 | 321.4 | 222.9 | 281.7 | 295.1 | 290.0 | 269.3 |
| EPS in Rs | 4.81 | 11.39 | 15.63 | 16.8 | 19.51 | 13.53 | 17.1 | 17.91 | 0 | 16.34 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 938.3 | 785.0 | 1,208.7 | 1,373.4 | 1,545.2 | 1,537.5 | 1,401.7 | 1,405.8 | 1,384.1 | 1,424.9 |
| Expenses | 648.7 | 616.6 | 914.7 | 1,049.3 | 1,188.8 | 1,178.8 | 1,137.3 | 1,108.8 | 1,024.1 | 1,077.4 |
| Operating Profit | 289.6 | 168.4 | 294.0 | 324.1 | 356.4 | 358.7 | 264.4 | 297.1 | 360.0 | 347.5 |
| OPM % | 30.86% | 21.45% | 24.32% | 23.6% | 23.06% | 23.33% | 18.86% | 21.13% | 26.01% | 24.39% |
| Other Income | 61.5 | -17.5 | 37.5 | 53.2 | 37.4 | 42.1 | 51.4 | 59.7 | 58.5 | 44.0 |
| Interest | 2.6 | 2.2 | 4.9 | 6.0 | 5.3 | 10.0 | 5.6 | 6.1 | 22.8 | 7.5 |
| Depreciation | 37.6 | 37.5 | 65.3 | 81.3 | 105.3 | 92.6 | 92.0 | 93.8 | 96.3 | 95.8 |
| Profit before tax | 310.9 | 167.6 | 261.3 | 289.9 | 283.2 | 298.2 | 218.2 | 256.8 | 299.3 | 288.3 |
| Tax % | -25.4% | -29.2% | -25.7% | -33% | -32.2% | -35.5% | 34.1% | 36.3% | 31.6% | -35.3% |
| Net Profit | 231.9 | 78.7 | 194.1 | 194.1 | 191.9 | 192.4 | 143.8 | 163.5 | 204.7 | 186.5 |
| EPS in Rs | 14.08 | 4.78 | 11.78 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 9% |
| 3 Years: | -2% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 7% |
| 3 Years: | -3% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | -19% |
| 1 Year: | -18% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 16% |
| 3 Years: | 8% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -2% |
| 3 Years: | -17% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | -19% |
| 1 Year: | -18% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|